Phase III randomized double-blind placebo-controlled multi-centre study assessing the efficacy and safety of durvalumab versus placebo as treatment following SBRT in patients with Stage I/II non small cell lung cancer.

Brief description of study

The purpose of this study by AstraZeneca AB is to find out if the medication called durvalumab will work and be safe for the treatment of patients with Stage I/II Non Small Cell Lung Cancer following stereotactic body radiation therapy.




If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.